HRP20120917T1 - TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA - Google Patents

TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA Download PDF

Info

Publication number
HRP20120917T1
HRP20120917T1 HRP20120917AT HRP20120917T HRP20120917T1 HR P20120917 T1 HRP20120917 T1 HR P20120917T1 HR P20120917A T HRP20120917A T HR P20120917AT HR P20120917 T HRP20120917 T HR P20120917T HR P20120917 T1 HRP20120917 T1 HR P20120917T1
Authority
HR
Croatia
Prior art keywords
image
compound
salt according
tetrahydrocyclopenta
cyano
Prior art date
Application number
HRP20120917AT
Other languages
English (en)
Croatian (hr)
Inventor
Prabhakar Kondaji Jadhav
Venkatesh Krishnan
Euibong Jemes Kim
Original Assignee
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly & Company filed Critical Eli Lilly & Company
Publication of HRP20120917T1 publication Critical patent/HRP20120917T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20120917AT 2008-05-16 2009-05-14 TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA HRP20120917T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5372208P 2008-05-16 2008-05-16
PCT/US2009/043875 WO2009140448A1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators

Publications (1)

Publication Number Publication Date
HRP20120917T1 true HRP20120917T1 (hr) 2012-12-31

Family

ID=40847864

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120917AT HRP20120917T1 (hr) 2008-05-16 2009-05-14 TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA

Country Status (18)

Country Link
US (1) US8486943B2 (cg-RX-API-DMAC7.html)
EP (1) EP2297100B1 (cg-RX-API-DMAC7.html)
JP (1) JP5603327B2 (cg-RX-API-DMAC7.html)
KR (1) KR101278788B1 (cg-RX-API-DMAC7.html)
CN (1) CN102026974B (cg-RX-API-DMAC7.html)
AU (1) AU2009246348B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2724629C (cg-RX-API-DMAC7.html)
CY (1) CY1113341T1 (cg-RX-API-DMAC7.html)
DK (1) DK2297100T3 (cg-RX-API-DMAC7.html)
EA (1) EA019713B1 (cg-RX-API-DMAC7.html)
ES (1) ES2396612T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120917T1 (cg-RX-API-DMAC7.html)
MX (1) MX2010012436A (cg-RX-API-DMAC7.html)
PL (1) PL2297100T3 (cg-RX-API-DMAC7.html)
PT (1) PT2297100E (cg-RX-API-DMAC7.html)
SI (1) SI2297100T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009140448A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
FI3122426T3 (fi) 2014-03-28 2023-03-31 Univ Duke Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
EP3474841B1 (en) 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물
EP4096660A1 (en) * 2020-01-27 2022-12-07 EirGen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US20230255933A1 (en) * 2020-07-06 2023-08-17 Crescenta Biosciences Antiviral use of fabp4 modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP2007526304A (ja) 2004-03-03 2007-09-13 イーライ リリー アンド カンパニー 二環式置換インドール誘導体ステロイドホルモン核内受容体モジュレータ
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
TW200640931A (en) * 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
WO2007002181A2 (en) * 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

Also Published As

Publication number Publication date
ES2396612T3 (es) 2013-02-22
AU2009246348B2 (en) 2012-04-12
AU2009246348A8 (en) 2010-12-16
EP2297100A1 (en) 2011-03-23
US8486943B2 (en) 2013-07-16
WO2009140448A8 (en) 2010-01-07
EA201071317A1 (ru) 2011-06-30
PL2297100T3 (pl) 2013-03-29
CA2724629A1 (en) 2009-11-19
DK2297100T3 (da) 2012-12-17
AU2009246348A1 (en) 2009-11-19
KR20100132551A (ko) 2010-12-17
KR101278788B1 (ko) 2013-06-25
EP2297100B1 (en) 2012-10-31
US20110039855A1 (en) 2011-02-17
EA019713B1 (ru) 2014-05-30
CY1113341T1 (el) 2016-06-22
JP5603327B2 (ja) 2014-10-08
PT2297100E (pt) 2013-01-24
MX2010012436A (es) 2010-12-06
JP2011520903A (ja) 2011-07-21
WO2009140448A1 (en) 2009-11-19
CA2724629C (en) 2014-08-19
CN102026974A (zh) 2011-04-20
SI2297100T1 (sl) 2013-02-28
CN102026974B (zh) 2013-08-28
BRPI0912394A2 (pt) 2016-07-26

Similar Documents

Publication Publication Date Title
HRP20120917T1 (hr) TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA
JP2011520903A5 (cg-RX-API-DMAC7.html)
FI4088720T3 (fi) Rimegepantti cgrp-liittyviin häiriöihin
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
JP2009504763A5 (cg-RX-API-DMAC7.html)
JP2010077141A5 (cg-RX-API-DMAC7.html)
HRP20161657T1 (hr) Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta
JP2009504764A5 (cg-RX-API-DMAC7.html)
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
WO2009140341A3 (en) Atorvastatin compositions
JP2013545785A5 (cg-RX-API-DMAC7.html)
GB2465897A (en) Respiratory disease treatment
WO2007087431A3 (en) Sublingual fentanyl spray
EP2966072A3 (en) Crystalline forms of nilotinib hydrobromide, succinate, glutamate, acetate, l-malate and maleate
WO2008063867A3 (en) Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators
SI2315587T1 (en) A therapeutic composition comprising macitentan
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
JP2011502997A5 (cg-RX-API-DMAC7.html)
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
HRP20160327T1 (hr) Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom
MX2019009841A (es) Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
RU2014109441A (ru) Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами